Toddy Sewell

MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

J. Blankenship, J. Gross, C. Mcmahan, 2016, Molecular Cancer Therapeutics.

Large Molecule Therapeutics MOR 209 / ES 414 , a Novel Bispeci fi c Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

J. Blankenship, J. Gross, C. Mcmahan, 2016 .

Quantitative Gene Expression Assays without Target Amplification

A. Lois, C. Lacerte, J. Tolley, 2003 .

Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques

D. Jablonski, J. Gross, D. Bienvenue, 2019, Immunology.

Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release

J. Gross, Robert E. Miller, D. Bienvenue, 2018, Immunology.

Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies

J. Blankenship, P. Pavlík, J. Gross, 2017 .

319 Anti-PSMA X Anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-resistant Prostate Cancer Models

J. Blankenship, P. Algate, S. Natarajan, 2012 .

Rapid assays for quantitating cytokine gene expression without target amplification.

A. Lois, C. Lacerte, J. Tolley, 2003, Combinatorial chemistry & high throughput screening.